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Nitric oxide (NO) has become recognized as a major effector
molecule in a diverse array of physiologic and pathologic
processes (Bredt and Snyder, 1994; Schmidt and Walter, 1994). It
has also become evident that this gas radical, produced by many
cells in the human body, not only controls important functions in
tumour progression, but may have a major influence on the
outcome of cancer therapies, particularly those that are mediated
by increased generation of reactive oxygen species (oxidative
stress) (Jenkins et al, 1995; Xie et al, 1995; Parkins et al, 1995;
Tozer and Everett, 1997a; Hirst and Flitney, 1997).
Photodynamic therapy (PDT), used for the treatment of various
types of cancer (Dougherty et al, 1998), induces a strong oxidative
stress and triggers the vascular-mediated response with a massive
neutrophil recruitment (Krosl et al, 1995; Gollnick et al, 1997),
and these events are prone to be highly sensitive to NO mediation
(Moilanen et al, 1993; Schmidt and Walter, 1994; Hirst and
Flitney, 1997). In tumours producing high levels of NO, the PDT-
induced reduction in tumour blood flow, vascular occlusion and
consequent ischaemia may be diminished, while the inflammatory
reaction triggered by PDT may be suppressed (Korbelik et al,
1998). This could result from the following effects of NO:
•Acts as a potent vasodilator.
•Prevents platelet aggregation and adhesion to the endothelium.
•Suppresses the aggregation of accumulated inflammatory
neutrophils.
•Inhibits the expression of leukocyte adhesion molecules 
and hence the adhesion and extravasation of circulating
leukocytes.
•Averts mast cell degranulation (Schmidt and Walter, 1994; 
Vanhoutte, 1987; Kubes et al, 1991).
On the other hand, elevated NO levels may maintain vessel dila-
tion during PDT light treatment, which can diminish the decrease
in tumour oxygenation and sustain in this way the oxygen-
dependent generation of phototoxic damage (Korbelik et al, 1998).
Additionally, NO increases vascular permeability and consequent
vascular leakage, which are characteristic occurrences in PDT-
treated vasculature (Dougherty et al, 1998). The NO-sensitive
processes that unfold after the termination of photodynamic light
treatment include:
•Ischaemia-reperfusion injury, where NO can have a 
protective role.
•Apoptosis of tumour cells, which can be stimulated by NO.
•Development of the immune reaction against the treated
tumour, where NO has immunoregulatory functions
(Korbelik et al, 1998; Dougherty et al, 1998).
The levels, as well as main cellular sources of endogenously
produced NO, vary considerably among solid human and animal
Nitric oxide production by tumour tissue: impact on the
response to photodynamic therapy
M Korbelik1, CS Parkins2, H Shibuya1, I Cecic1, MRL Stratford2 and DJ Chaplin2
1Cancer Imaging Department, British Columbia Cancer Agency, 601 West 10th Avenue, Vancouver BC, Canada; 2Gray Laboratory Cancer Research Trust,
Northwood, Middlesex, UK
Summary The role of nitric oxide (NO) in the response to Photofrin-based photodynamic therapy (PDT) was investigated using mouse
tumour models characterized by either relatively high or low endogenous NO production (RIF and SCCVII vs EMT6 and FsaR, respectively).
The NO synthase inhibitors Nw-nitro-L-arginine (L-NNA) or Nw-nitro-L-arginine methyl ester (L-NAME), administered to mice immediately after
PDT light treatment of subcutaneously growing tumours, markedly enhanced the cure rate of RIF and SCCVII models, but produced no
obvious benefit with the EMT6 and FsaR models. Laser Doppler flowmetry measurement revealed that both L-NNA and L-NAME strongly
inhibit blood flow in RIF and SCCVII tumours, but not in EMT6 and FsaR tumours. When injected intravenously immediately after PDT light
treatment, L-NAME dramatically augmented the decrease in blood flow in SCCVII tumours induced by PDT. The pattern of blood flow
alterations in tumours following PDT indicates that, even with curative doses, regular circulation may be restored in some vessels after
episodes of partial or complete obstruction. Such conditions are conducive to the induction of ischaemia-reperfusion injury, which is instigated
by the formation of superoxide radical. The administration of superoxide dismutase immediately after PDT resulted in a decrease in tumour
cure rates, thus confirming the involvement of superoxide in the anti-tumour effect. The results of this study demonstrate that NO participates
in the events associated with PDT-mediated tumour destruction, particularly in the vascular response that is of critical importance for the
curative outcome of this therapy. The level of endogenous production of NO in tumours appears to be one of the determinants of sensitivity to
PDT. © 2000 Cancer Research Campaign
Keywords: photodynamic therapy; nitric oxide; ischaemia-reperfusion injury; mouse tumour models; tumour blood flow; nitric oxide
synthase inhibitors
1835
Received 27 July 1999
Revised 4 January 2000
Accepted 2 February 2000
Correspondence to: M Korbelik
British Journal of Cancer (2000) 82(11), 1835–1843
© 2000 Cancer Research Campaign
DOI: 10.1054/ bjoc.2000.1157, available online at http://www.idealibrary.com on tumours (Tozer and Everett, 1997b; Parkins et al, 1995). Since NO
acts as a vasodilator, its generation may be upregulated in some
tumours to compensate for deficient blood supply. Indeed, NO
appears to act in the signalling cascade for tumour neovasculariza-
tion (Jenkins et al, 1995). In a preliminary report, we have
suggested that endogenous NO production may represent an
important determinant in the response of tumours to PDT
(Korbelik et al, 1997).
Marked changes in tumour NO levels may be expected to occur
after photodynamic treatment. An increase in the generation of NO
was observed following PDT treatment of tumour cells in vitro
(Gupta et al, 1998). This was attributed to the enhanced expression
of the constitutive form of nitric oxide synthase (NOS), observed
to peak at 5 min post-PDT and return to normal levels within
60 min. The increased activity of this Ca2+-regulated NOS
isoform, which could be tumour type- and PDT photosensitizer-
dependent, may be triggered by the PDT-induced release of intra-
cellular calcium stores (Ochsner, 1997). Moreover, the interaction
of PDT-based oxidative stress with cellular signal transduction
pathways leads to the activation of nuclear transcription factors
(Dougherty et al, 1998), which may also result in the upregulation
of genes encoding NOS. On the other hand, activated inflamma-
tory cells accumulated in PDT-treated tumours may be responsible
themselves for the release of NO (Cecic and Korbelik, 1999;
McCall et al, 1989; Mehta et al, 1991; Evans et al, 1996). In
contrast, a decreased release of NO can be expected if its main
source is impaired by cytotoxic damage inflicted by PDT to cells
largely responsible for endogenous NO production (e.g. endothe-
lial cells in tumour vasculature) (Gilissen et al, 1993).
From the above consideration it is clear that the NO levels in
tumours and their modulation may considerably impact the cura-
tive result of PDT. In the present study, we have investigated the
effect of NOS inhibitors on the PDT response of mouse tumours
characterized by a different production of endogenous NO.
MATERIALS AND METHODS
Tumour models
Squamous cell carcinoma SCCVII (Suit et al, 1985), as well as
fibrosarcomas RIF-1 (Twentyman et al, 1980) and FsaR (Volpe et
al, 1985) were implanted into syngeneic C3H/HeN mice, while
mammary sarcoma EMT6 (Rockwell et al, 1972) was implanted
into syngeneic BALB/c mice. For experiments, the tumours were
inoculated subcutaneously in lower dorsal region of 7–9 week old
female mice. The exception was blood flow experiments, for
which the tumours were implanted in the dorsal side of hind left
footpads. Details of maintenance and implantation of these
tumours have been reported earlier (Korbelik and Krosl, 1996a).
Chemicals
All drugs were purchased from Sigma Chemical Co. (St. Louis,
MO, USA). The NOS inhibitors used were Nw-nitro-L-arginine
(L-NNA) (Sigma N-5501) and Nw-nitro-L-arginine methyl ester
(L-NAME) (Sigma N-5751). The inactive analogue Nw-nitro-D-
arginine methyl ester (D-NAME) (Sigma N-4770) was also tested.
These arginine analogues were administered at 20 mg kg–1 (0.1 ml
per 20 g body weight). Superoxide dismutase (SOD) (Sigma
S-5639), a manganese-containing enzyme (EC 1.15.1.1), was
administered at 450 U per mouse. The same SOD dose was used in
a previous work (Parkins et al, 1995). All these compounds were
dissolved in 5% dextrose solution and injected intravenously.
Analysis of NO production using tumour explants
The exact procedure has been described previously (Parkins et al,
1995). Briefly, the excised tumours were weighed, finely minced
and incubated in small Petri dishes containing nitrate-free Minimal
Essential Medium Eagle (Sigma M-4655) supplemented with 10%
FBS (Hyclone Laboratories, Inc., Logan, UT). Aliquots of culture
supernatants collected at different time-points after incubation at
37°C in a humidified CO2-air incubator were analysed by high-
performance ion chromatography (HPIC) for the concentration of
the NO metabolites nitrite and nitrate (Stratford et al, 1997). All
the samples collected in the present study showed no significant
accumulation of nitrite (NO is oxidized to nitrite first and subse-
quently to nitrate if haemoglobin or other serum proteins are
present). At least four identical tumour explant cultures were used
for each determination. The size of these tumours was similar to
that used for PDT (see below).
In some experiments, the production of NO was assessed using
a modified NOS assay (Rees et al, 1995). In this case, 0.5 mCi of
L-[14C]arginine (278 mCi mmol–1) purchased from Amersham Life
Science (Buckinghamshire, UK) was added to tumour explant
medium during 1 h incubation at 37°C. NOS activity was deter-
mined from the conversion of L-[14C]arginine to L-[14C]citrulline
using a kit produced by Cayman Chemical Company (Ann Arbor,
MI, USA).
PDT treatment
One week after inoculation, tumours reached 5–6 mm in largest
diameter and the host mice were administered Photofrin (porfimer
sodium, QLT PhotoTherapeutics, Inc., Vancouver, Canada) at
10 mg kg–1 i.v. The light treatment was performed 24 h later with
doses ranging from 75–180 J cm–2, depending on the tumour
model. Specially designed lead holders were used for immobi-
lizing the mice during PDT illumination without anaesthesia. The
tumours and 1 mm of surrounding normal skin were treated super-
ficially with 630 ± 10 nm light delivered from a tunable light
source based on a 1 kW xenon bulb (Model A5000; Photon
Technology International, Inc.) through a 5 mm core diameter
liquid light guide (2000A; Luminex, Munich, Germany). The
power density at the treatment area was 60–70 m W cm–2.
Evaluation of tumour response
After treatment with PDT and/or other agents, mice were observed
for tumour regrowth every second day until 90 days post-PDT, at
which time mice showing no sign of tumour were considered
cured. Each treatment group consisted of eight mice. In the case of
treatment with NOS inhibitors only (no PDT), changes in tumour
volumes were determined by measuring with a caliper the lesion’s
three orthogonal diameters.
Measurement of tumour blood flow
The procedure based on laser Doppler flowmetry was identical to
that described by Durand and LePard (1994) and was performed in
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exposing their tumour-bearing leg; tumour size was as described
for PDT treatment. Blood flow in superficial tumour regions was
measured using a laser Doppler flowmeter (Laserflo Perfusion
Monitor, Model BPM 403; TSI, Inc., St Paul, Minnesota, USA),
which registers tissue microvascular flow continuously and non-
invasively with a spatial resolution of approximately 1 mm3
(Shepherd et al, 1987). The contribution of the superficial skin was
found not to obscure tumour-related blood flow changes measured
by this instrument (Durand and LePard, 1994). The needle probe
with a 0.7 mm tip diameter was placed directly on the skin above
the tumour. A winged needle infusion set connected to a syringe
containing NOS inhibitor solution was installed into the tail vein
of mice before the onset of blood flow measurement. The drug was
injected as a bolus (0.1 ml per 20 g body weight) after 30 min
recording pre-treatment blood flow. The values for relative blood
flow were derived from the number and velocity of moving red
blood cells, normalized to the mean pre-treatment value. During
the PDT treatment, the laser Doppler flowmetry was stopped and
then resumed immediately after the termination of PDT illumina-
tion, by carefully repositioning the needle probe on the tumour
precisely at the pre-treatment site.
Statistical analysis of the tumour response data was performed
using the long-rank test and other data were analysed using
Student’s  t-test.
RESULTS
A previous report (Parkins et al, 1995) has shown that the intrinsic
production of NO can considerably vary with different types of
mouse tumours. This is also exemplified in Figure 1, which depicts
the results of NO production measurement in four mouse tumour
models. Explants of freshly excised tumour tissue were incubated
ex vivo for 6–24 hours and the oxidized metabolites of NO (nitrite
and nitrate) released in the culture medium were analysed by
HPIC. Since no significant accumulation of nitrite was detected,
the production of NO was assessed based on the increase of nitrate
in the explant medium. The results show that RIF and SCCVII
tumours are more active producers of NO than FsaR and EMT6
tumours. For instance, RIF tumours produced approximately four-
fold more NO than EMT6 tumours. The presence of NO synthase
inhibitor L-NNA (1 mM) in the explant medium suppressed the
production of NO by these tumours, as illustrated with the SCCVII
explants (Figure 1). An alternate method of NO production
measurement, a modified version of NOS assay based on 14C-
labelled  L-arginine described by Rees et al (1995), produced equiv-
alent results. The NOS activity (pmol hour–1 mg–1 protein ± SD)
in SCCVII, RIF, EMT6 and FsaR tumours was 8.36 ± 1.19,
13.41 ± 8.66, 2.56 ± 1.07, and 0.69 ± 0.44, respectively.
As alluded to above, local levels of NO may influence the
response of tumours to therapeutic modalities such as PDT. This
was tested by examining the effect of a single treatment with NOS
inhibitors L-NNA and L-NAME on the response of ‘low’ (FsaR
and EMT6) and ‘high’ NO producing tumours (SCCVII and RIF)
to Photofrin-based PDT. The effect of a single injection of L-NNA
or L-NAME at doses used in these experiments showed no signifi-
cant effect on tumour growth. An example is depicted in Figure 2,
which shows that L-NNA produced an apparent but statistically
insignificant temporary retardation of the growth of SCCVII
tumours.
The photosensitizer and light dose combination used for the
treatment of SCCVII tumours produced their complete initial abla-
tion, but all the tumours re-grew within 2–3 weeks (Figure 3). In
contrast, in mice that received L-NAME or L-NNA (20 mg kg–1
i.v.) immediately after the termination of photodynamic light treat-
ment, 40–50% of tumours remained non-palpable over 90 days
after treatment, which qualifies as tumour cure. Similar results
were obtained with RIF tumours, as illustrated for the PDT plus L-
NAME combination in Figure 3. While the chosen PDT-only treat-
ment was not curative, over 60% of RIF tumours were cured when
L-NAME was injected immediately after PDT. As shown in the
same graph, delaying the L-NAME administration to 30 min or
24 h after PDT abrogated the beneficial effect on the tumour
Nitric oxide and tumour PDT response 1837
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Figure 1 The production of NO by mouse tumours measured during ex-
vivo explant culture. Subcutaneously growing EMT6, FsaR, SCCVII and RIF
tumours were excised and cultured ex vivo for either 6 or 24 h. The
production of NO in tumours was determined from aliquots of culture
supernatants analysed for its oxidized product, nitrate. The NOS inhibitor L-
NNA (1 mM) was added to some SCCVII explant cultures. Significantly
greater nitrate was produced by SCCVII and RIF tumours compared with
EMT6 and FsaR tumours (Bars, SD; * = P < 0.005).
Figure 2 The effect of L-NNA on growth of subcutaneous SCCVII tumours.
The drug was administered intravenously (20 mg kg–1) at 6 days post-tumour
implant. Changes in tumour volumes were monitored for 16 days after
L-NNA injection.response. The administration of NOS inhibitors before the PDT
light treatment diminished the curative effect of PDT (Korbelik
and Krosl, 1996b), presumably because of reduced tumour
oxygenation during light treatment (Wood et al, 1994).
The adjuvant treatment with NOS inhibitors produced no thera-
peutic benefit with PDT-treated FsaR and EMT6 tumours. The
examples for L-NNA with FsaR tumours and for L-NAME with
EMT6 tumours (the drugs injected immediately after PDT),
depicted in Figure 3, show that no significant difference in tumour
cures was obtained between PDT-only and PDT plus L-NNA/L-
NAME treatment groups. The results with these two tumour
models indicate that they exhibit greater intrinsic sensitivity to
PDT than RIF and SCCVII tumours.
The NOS inhibitors L-NNA and L-NAME are known to induce
the inhibition of tumour blood flow (Andrade et al, 1992; Horsman
et al, 1996), but no evidence is available on the relevance of the
level of intrinsic NO production in tumours for the expression of
this effect. The effects of these two drugs on tumour blood flow in
the four models used in this study are shown in Figure 4. The
results of blood flow measurement, using laser Doppler
flowmetry, in four representative individual tumours growing in
mice injected with L-NNA are shown on the left. It is evident that
this drug induced a different response in RIF tumours than in FsaR
tumours, which were growing in the same strain of mice. The
blood flow in RIF tumours started to decrease within 5 min after
L-NNA injection, dropped to 20–50% of normal values during the
next 10–
15 min, and showed little, if any, signs of recovery at 60 min
post-drug administration. In contrast, the blood flow of low NO
producing FsaR tumours was either moderately decreased or
showed no obvious changes. At 30 min after the L-NNA injection,
the relative blood flow levels in RIF and FsaR tumours were
0.40  ± 0.22 and 0.81 ± 0.18 (means ± SD, n = 4), respectively.
The effects of L-NAME on the blood flow in RIF, SCCVII and
EMT6 tumours, presented in this case as average values from
measurements in 3–4 tumours, are shown in the right side graph
of Figure 4. The inhibitory effect of this drug was clearly evident
with the blood flow in RIF and SCCVII tumours, showing a
similar pattern as depicted for L-NNA in RIF tumours. However,
in parallel with the situation shown for L-NNA with FsaR
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Figure 3 The effects of L-NNA and L-NAME on the response of various tumour models to PDT. Tumours growing in syngeneic mice were treated with light
(150 J cm–2 for SCCVII and FsaR, 180 J cm–2 for RIF, and 75 J cm–2 for EMT6) at 24 h after Photofrin administration (10 mg kg–1 i.v.). L-NNA or L-NAME were
injected immediately after light treatment (both at 20 mg kg–1 i.v.). The mice were thereafter monitored for signs of tumour growth or its absence. Eight tumour-
bearing mice were treated in each experimental group. * = P < 0.05 (compared to PDT only).tumours, L-NAME exerted no apparent influence on the blood
flow of the low NO producing EMT6 tumours. Also shown in the
same graph (Figure 4, right) is the result obtained with D-NAME
(RIF tumours), demonstrating that this metabolically inactive
analogue of L-NAME is ineffective as a tumour blood flow
inhibitor.
Since the effects of L-NAME on tumour blood flow correlate
with its beneficial action on tumour response in combination with
PDT, it was warranted to examine the effect of this drug on the
blood flow of PDT-treated tumours. The PDT dose used in the
experiments presented in Figure 3 promptly reduced the blood
flow of treated SCCVII tumours to approximately 50% of normal
levels, as shown with the examples of four individual tumours in
Figure 5. However, this inhibitory effect generally lasted no longer
than 20 minutes and then the blood flow was largely restored or
Nitric oxide and tumour PDT response 1839
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Figure 5 The effect of L-NAME on the tumour blood flow changes induced
by PDT. Mice bearing SCCVII tumours were given Photofrin (10 mg kg–1 i.v.)
followed 24 h later by 150 J cm–2 of tumour-localized red light. Some of the
mice were also injected L-NAME (20 mg kg–1 i.v.) immediately after light
treatment. Tumour blood flow was recorded before and after PDT as
described in Figure 3. Individual traces are shown of four mice treated either
by PDT alone (open symbols) or five mice treated by PDT plus L-NAME
(closed symbols).even temporarily increased above normal levels in some tumours.
In contrast, the blood flow in tumours of mice injected with
L-NAME immediately after PDT was more profoundly reduced
(to 10–30% of normal levels) and showed no signs of recovery up
to the end of measurement (60–70 min post PDT); examples of
five individual tumours are shown in Figure 5.
The observed pattern of changes in SCCVII tumour blood flow
following PDT alone suggests that this treatment may induce
ischaemia (as a consequence of the pronounced decrease in blood
circulation) followed by reperfusion due to the restored normal
blood flow. This can be associated with classical ischaemia-
reperfusion injury, characterized by the production of superoxide
in the treated tumour vasculature, which can contribute to the anti-
tumour effect of PDT. To test this possibility, we have examined
the effect of superoxide dismutase (SOD) on the tumour PDT
response. The enzyme was injected intravenously immediately
after the termination of PDT light treatment. The results with
EMT6 and FsaR tumours show that the treatment with SOD
markedly decreases the curative effect of PDT, while with SCCVII
tumours this impact is much less pronounced and statistically
insignificant (Figure 6). This finding corroborates the assumption
that superoxide is formed after PDT and that the inhibition of its
formation can be detrimental to the curative outcome of PDT,
particularly with low NO-producing tumours. The inter-experi-
mental variations in the PDT only response of EMT6 and FsaR
tumours that can be noted in Figures 3 and 6 most likely originate
from differences between cohort of tumours implanted at different
times.
DISCUSSION
In this study, we have used four mouse tumour models, two of
which (RIF and SCCVII) are characterized by at least several-fold
higher endogenous production of NO than the other two (EMT6
and FsaR). This qualification is based on the measurement of NO
production using an in vitro assay in which tumour explants are
fully oxygenated. This may not represent the actual in vivo tumour
microenvironment characterized by the presence of variable sizes
of hypoxic fraction in which NOS activity is arrested. Although
showing marked heterogeneity, the hypoxic fraction is generally
dependent of tumour size (Moulder and Rockwell, 1984), which in
our experiments ranged 5–7 mm (largest diameter). At these sizes,
hypoxic fractions may be large in EMT6 (> 30%), but not in
SCCVII and FsaR (< 10%), and even less so in RIF tumours
(< 2%) (Moulder and Rockwell, 1984; 1987). Thus, the size of the
hypoxic fraction does not appear to determine our classification of
tumours as high and low NO producers.
Alternate methods of NO measurement have other limitations.
Probes inserted for in situ measurement damage blood vessels and
may perturb tumour oxygenation, while immunohistochemistry
assays do not quantify NOS activity in vivo. The advantage of the
assay chosen in this study is that total NO production is tested
under controlled conditions, containing fixed oxygenation and
supply of co-factors, thereby allowing direct comparisons between
tumour types. Our results show that the above classified two
groups of tumours respond differently to the NO modulation treat-
ments performed either alone or in conjunction with PDT.
In tumour models characterized by relatively high production of
NO, lowering the NO levels immediately after PDT (by intra-
venously administered NOS inhibitors) appears to enhance the
degree of destruction of treated tumours, as suggested by the
improved tumour cure rates. Regular blood flow in these tumours
appears to be maintained by a constant vasodilatation exerted
through the presence of NO, as indicated by a strong impact of
NOS inhibitors L-NNA and L-NAME (Figure 4). Moreover, NO
has an important role in the restitution of PDT-inhibited tumour
blood flow in those vessels that are not permanently damaged,
since a more profound and longer lasting inhibition of tumour
blood flow was observed with the L-NAME injection combined
with PDT (Figure 5). On the other hand, tumours producing rela-
tively low levels of NO (EMT6 and FsaR) are more sensitive to
PDT, their blood perfusion is much less dependent on NO (showing
very little, if any, sensitivity to the treatment with NOS inhibitors),
and their PDT-mediated cure rate cannot be improved by NO level
modulation. These results demonstrate that NO has an important
role in events critical for the therapeutic outcome of PDT.
1840 M Korbelik et al
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Figure 6 The effect of superoxide dismutase (SOD) on the response of
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statistically significant (P < 0.05) in the top two graphs.Depending on tumour genotype and/or the level of its produc-
tion, NO may play a facilitory or inhibitory role in tumour progres-
sion. The latter relates to the fact that high (micromolar) NO
concentrations are cytotoxic (Schulz and Wambolt, 1995; Lala and
Orucevic, 1998). The facilitory role NO exerts through the promo-
tion of tumour blood flow (highly relevant for the effects investi-
gated in this study), induction of angiogenesis in tumours
(Fukumura and Jain, 1998; Lala and Orucevic, 1998) and promo-
tion of tumour-cell invasiveness (Orucevic et al, 1999). In the
present study, the modulation of NO levels achieved by a single
treatment with NOS inhibitors was sufficient for a short-term
modulation of tumour blood flow, but had no obvious impact on
these other roles of NO in tumour progression, as evidenced by the
absence of significant retardation of tumour growth (Figure 2).
Other authors (van Geel et al, 1994, 1996) already documented
the induction of blood flow decrease by PDT in SCCVII and RIF
tumour models. Results in our laboratory suggest that the intensity
of this response is dependent on the PDT dose. The dose used in
the experiments presented in Figure 5 is just below the curative
threshold, and higher (curative) doses produce more pronounced
or even permanent inhibition of blood flow in SCCVII and other
tumour models (data not shown). However, even at relatively high
PDT doses, vessel reperfusion may occur in tumour regions most
distant to the source of illumination. The existence of episodes of
partial or complete obstruction and subsequent restoration of
tumour blood flow is of particular interest, because they may be
associated with the induction of ischaemia-reperfusion injury
(Kimura et al, 1996). During ischaemia, metabolic breakdown of
ATP leads to the accumulation of xanthine/hypoxanthine and
increased levels of xanthine oxidase (Grisham et al, 1986; Parkins
et al, 1997). Consequently, a sudden re-introduction of oxygen at
the time of reperfusion will result in a massive generation of super-
oxide in the affected tumour vasculature (Parkins et al, 1998). The
presence of this oxygen radical in tumours following PDT was
indirectly confirmed by the effect of SOD treatment on tumour
cures (Figure 6). Since intravenously injected SOD is not likely to
reach perivascular regions (or even endothelium), it can be
concluded that a significant generation of oxygen radicals occurs
in the vessel lumen of PDT-treated tumours. Earlier reports have
also demonstrated the generation of superoxide in the skin of mice
following PDT using ESR spectroscopy (Athar et al, 1988), and
shown that the PDT effect can be inhibited by a SOD mimic
compound or augmented by a SOD inhibitor (Athar et al, 1989).
The results of the experiments with SOD (Fig. 6) suggest that
superoxide generated following tumour PDT treatment can
contribute to the curative outcome both directly through inducing
oxidative stress at the endothelium and indirectly through the
interaction with NO. Because NO contains an unpaired electron
and is paramagnetic, it rapidly reacts with superoxide forming
peroxynitrite anion (ONOO–) (Blough and Zalfiriou, 1985; McCall
et al, 1989). Since very modest, if any, effect on PDT response is
observed with high NO-producing SCCVII tumours, it may be
speculated that under elevated NO concentrations superoxide is
detoxified without reducing NO levels below the critical threshold.
In contrast, under reduced NO concentrations present in EMT6
and FsaR tumours, NO levels may be further depleted through the
interaction with PDT-generated superoxide, whereby superoxide
may not be completely detoxified. Consequently, the administra-
tion of SOD following PDT treatment of these tumours results in
scavenging of superoxide, which diminishes superoxide-mediated
injury. Although it was suggested that SOD may act as a vascular
modulator (Beckman et al, 1990), it is more likely that this effect
is mediated through the interaction of superoxide with NO
(Nakazono et al, 1991; Wolin, 1996).
Ischaemia-reperfusion insult is primarily inflicted by activated
neutrophils massively invading the affected site (mediated through
superoxide-induced upregulation of P-selectin) that induce consid-
erable damage to the vasculature and surrounding tissue (Gaboury
et al, 1994). The existence of a pronounced influx of neutrophils
into PDT-treated tumours has been well-documented (Krosl et al,
1995; Gollnick et al, 1997; Korbelik and Cecic, 1998). Studies
based on an experimental model of ischaemia-reperfusion injury
induced by transiently clamping the feeding blood vessels to
subcutaneous mouse tumours have demonstrated that this type of
insult can produce significant generation of oxygen radicals
leading to tumour cytotoxicity (Parkins et al, 1995; 1998). In these
reports, it was also shown that NO exerts a strong protective role in
this type of injury, since it affects more profoundly low NO-
producing tumours and is potentiated by the L-NNA treatment.
Endogenous NO production may also be one of the determinants
of tumour sensitivity to PDT. This is indicated by the fact that
EMT6 and FsaR tumours, ‘low’ NO producers, exhibit markedly
greater sensitivity to PDT than ‘high’ NO producing RIF and
SCCVII tumours. This property, if verified by more detailed
experimental evidence, will deserve to be evaluated as a potential
prognostic indicator for the outcome of PDT.
Further investigation needs to clarify which NOS isoforms
(constitutional or inducible) are responsible for the endogenous
NO production in chosen tumour models, and which cells are its
main source. The PDT-induced changes in NO production in
treated tumours have to be better characterized, particularly the
NO-generating activity of neutrophils accumulating in PDT-
treated lesions. As emphasized above, there are a number of events
associated with PDT tumour responses that are influenced by the
presence of NO. It can be assumed that, in addition to influencing
blood flow and oxygen availability, NO controls the activity of
platelets, neutrophils and other leukocytes, as well as the release of
inflammatory mediators in the vasculature of PDT-treated tumours
(Korbelik et al, 1998), and this merits further investigation.
Note added in proof
After this paper was submitted for publication, a report was
published by Henderson et al (1999). In this work, the authors
show that the NOS inhibitor L-NNA, under conditions similar as
in this study, affects the cure rate and blood flow in PDT-treated
RIF tumours in a similar way as described in this report.
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